登录  
 加关注
查看详情
   显示下一条  |  关闭
温馨提示!由于新浪微博认证机制调整,您的新浪微博帐号绑定已过期,请重新绑定!立即重新绑定新浪微博》  |  关闭

青山妩媚

新的一年,新的心情,新的挑战,新的起点...

 
 
 

日志

 
 

2007 Top 20 Pharmaceutical/Biopharmaceutical Companies Report   

2009-01-31 13:41:16|  分类: Bio-Pharma |  标签: |举报 |字号 订阅

  下载LOFTER 我的照片书  |

2007 Top 20 Pharmaceutical Companies Report



Pfizer's at the top of the roost, but one hare-brained mega-acquisition by GlaxoSmithKline or Sanofi could topple them. Companies #2-5 are all foreign, but seven of the next eight are based in the U.S.; I have no idea what that's supposed to signify. Demonstrating how tough it is to stay at the top, only four companies in the top 10 reached double-digit sales growth.

The largest increase in revenues was Novartis' $3.3 billion, but almost 30%?of that came from its purchase of Chiron.?GSK had the greatest "organic"? growth, adding $3.0 billion in revenues. Bristol-Myers Squibb and Abbott Laboratories suffered the most last year, shedding $1.4 billion and $1.3 billion in revenues, respectively.

Several companies near the bottom of our list moved up thanks to strategic acquisitions; Bayer's purchase of Schering AG led to the biggest jump by any company on the list, from #20 to #16. Let's hope no one else gets any bright ideas . . .

—Gil Y. Roth, Editor

Top 20 Pharmaceutical Companies
01 Pfizer $45,083
02 GlaxoSmithKline $37,003
03 Sanofi-Aventis $35,643
04 AstraZeneca $25,741
05 Novartis $23,532
06 Merck $23,425
07 Johnson & Johnson $23,267
08 Roche $19,300
09 Wyeth $15,683
10 Eli Lilly & Co. $14,816
11 Bristol-Myers Squibb $13,861
12 Abbott Laboratories $12,395
13 Schering-Plough $10,461
14 Boehringer-Ingelheim $10,440
15 Takeda $9,793
16 Bayer AG $8,518
17 Astellas $7,862
18 Daiichi-Sankyo $7,166
19 Eisai $5,589
20 Merck KgA $4,674

Based on 2006 pharma revenues.
Note: In all Top Company profiles, dollar amounts are in millions.
For the online edition, pipeline and patent expiry info is only available for companies #1-5.

Contributors


Editor: Gil Y. Roth
Associate Editor: Kristin Brooks
Contributing Editor: Derek B. Lowe
All profiles written by Gil Roth, except Abbott Laboratories and Boehringer-Ingelheim, by Kristin Brooks

2007 Top 10 Biopharmaceutical Companies Report



Warts and all, Amgen remains at the apex of the Top 10 Biopharma rankings. The first half of 2007 was none too kind to the top gun, but Amgen still has a comfortable lead over its competitors on this list.

Speaking of which, there are a pair of new entries at #3 and #4! After putting Novo Nordisk on the Top 20 Pharma list last year, I decided that it would be more suited to the Top Biopharma ranks, especially since it announced that it was closing down all small molecule R&D. And UCB?Group made its way onto our list after last year's edition came out and members of the company called to explain (patiently) why UCB?should truly be considered a Biopharma (a lot of companies misuse the term, in my opinion). Their argument made enough sense for me to add them to this year's ranks.

Also, Chiron dropped from the list after being bought by Novartis. Serono and MedImmune will follow suit in next year's edition.

—Gil Y. Roth, Editor

Top 10 Biopharmaceutical Companies
01 Amgen $13,858
02 Genentech $7,640
03 Novo Nordisk $6,526
04 UCB Group $2,711
05 Biogen Idec $2,592
06 Gilead Sciences $2,588
07 Serono $2,498
08 Genzyme $2,278
09 MedImmune $1,221
10 Millennium $220

Based on 2006 biopharma revenues.
Note: In all Top Company profiles, dollar amounts are in millions.
For the online edition, pipeline and patent expiry info is only available for companies #1-3.

Contributors


Editor: Gil Y. Roth
Associate Editor: Kristin Brooks
Contributing Editor: Derek B. Lowe
All profiles written by Gil Roth.
  评论这张
 
阅读(305)| 评论(0)

历史上的今天

评论

<#--最新日志,群博日志--> <#--推荐日志--> <#--引用记录--> <#--博主推荐--> <#--随机阅读--> <#--首页推荐--> <#--历史上的今天--> <#--被推荐日志--> <#--上一篇,下一篇--> <#-- 热度 --> <#-- 网易新闻广告 --> <#--右边模块结构--> <#--评论模块结构--> <#--引用模块结构--> <#--博主发起的投票-->
 
 
 
 
 
 
 
 
 
 
 
 
 
 

页脚

网易公司版权所有 ©1997-2018